Quote #1: "Biogen, in turn, now seems destined to be a player on the merger and acquisition scene early in 2021. The good news is that there is a surfeit of takeover targets that would dovetail nicely with the biotech's core area of expertise. "
[Reference] https://www.fool.com/investing/2020/11/09/why-biogen-stock-is-tanking-today/
______________________________________________________________________________________________________
Quote #2: "Meanwhile, Biogen’s existing business is unlikely to excite investors soon. Its bestselling multiple-sclerosis drug Tecfidera faces competition from several cheap generic drugs. Total revenue fell 6% from a year earlier in the third quarter and Biogen lowered its full-year sales and profit outlook. The company at the same time authorized a fresh $5 billion in share repurchases, and if aducanumab doesn’t reach the market, it could turn to buying smaller biotech companies."
[Reference] https://www.wsj.com/articles/biogen-stock-might-not-recover-from-alzheimers-treatment-setback-11604921407?
